Summary: The aim of this research is to clarify the in‰uence of the viscosity of the nasal formulation on in vivo nasal drug absorption and its mechanism using an in vitro Caco-2 system. The drug solution was made viscous by the addition of dextran (Dex). The disappearance of FITC-labeled Dextran (FD, a marker of the dosing solution) applied with control solution followed monoexponential kinetics, while FD applied with Dex solution showed biexponential elimination. The mean residence time of FD in the nasal cavity was increased with the increase in Dex concentration. The nasal absorption of acyclovir was similar in the formulation with low viscosity, increased in the formulation with moderate viscosity and markedly decreased in the formulation with high viscosity. The result from the normal Caco-2 transport study could not explain the relation of in vivo drug absorption with viscosity, while the modiˆed Caco-2 system provided data partly re‰ecting the change in in vivo absorption in rats. In conclusion, the residence of the applied solution in the nasal cavity was enhanced by the addition of Dex in a viscositydependent manner. Moderate viscosity of the dosing solution improved the in vivo nasal absorption of acyclovir, while higher viscosity decreased it.
Introduction
Nasal delivery is a promising alternative for the systemic application of drugs that are poorly absorbed via the oral route. The nasal epithelium has relatively high permeability and only two cell layers separate the nasal lumen from the dense blood vessel network in the lamina propria. [1] [2] Consequently, the nasal route has drawn the attention of many researchers as a systemic delivery route of peptide drugs. In addition, avoidance of theˆrst hepatic passage makes nasal administration a promising alternative, especially for drugs exhibiting high metabolism in the intestine and W or liver. 3) A drug applied in the nasal cavity is translocated to the nasopharynx and thereafter to the GI tract by the coordinated beat of the cilia of respiratory epithelial cells. [4] [5] [6] This is an important nonspeciˆc defense mechanism of the respiratory tract and is called mucociliary clearance (MC). In order to improve nasal drug absorption, a powder formulation [7] [8] [9] [10] and W or bioadhesive gel formulation [11] [12] [13] [14] are applied nasally. Since the nasal absorption of drugs is generally better than intestinal absorption, the aim of powder and gel formulations is to enhance the nasal retention of the drug by the inhibition of MC. The use of a powder or gel formulation very simply and easily enhances drug absorption; however, little research has clariˆed the quantitative relation of drug retention in the nasal cavity and nasal drug absorption to the viscosity of the dosing solution.
In our previous report, the theory and calculation to evaluate the nasal and intestinal absorption following nasal drug administration in the normal physiologic condition were described.
15) It was also clariˆed that the contribution of the nasal cavity and the GI tract to the total absorption of nasally applied drugs is dependent on the physicochemical property of the drug. MC is a very important factor to determine the absorption proˆle of nasally applied drugs. The aim of this research is to clarify the in‰uence of the viscosity of the formulation on MC and drug absorption following nasal application. The modiˆed Caco-2 transport experiment was employed to clarify the mechanism of the change in the in vivo absorption of the drug.
Materials and Methods

Materials
Acyclovir and FITC-dextran (average Mw: 70 kDa; FD) were purchased from Sigma-Aldrich (St Louis, MO, USA). Dextran (Mw: 50,000-70,000; Dex), dithiothreitol (DTT) and phosphate-buŠered saline (pH7.4; PBS) were purchased from Nacalai Tesque Co. (Kyoto, Japan). Caco-2 cells were obtained from Dainippon Pharmaceuticals Co. (Osaka, Japan). Reagents and the medium used for Caco-2 culture, and the preparation of the monolayer were purchased from Sigma-Aldrich (St Louis, MO, USA), Gibco Laboratories (Lenexa, KS, USA) and Beckton Dickinson Biosciences (Bedford, MA, USA). All other chemicals were of reagent grade and commercially available.
Measurement of viscosity
The viscosity of Dex solutions was measured by the rheometer (HADV-III, LVDV-III, Brookˆeld Engineering, Middleboro, MA, USA) at 379 C.
Animal study
All animal studies were previously approved by the Committee of the Animal Care of Shujitsu University and conducted under the Guidelines. Male Wistar rats (B.W. 200-260 g) were used in all animal experiments. Rats used for nasal absorption studies were fasted overnight before the experiment.
Mucociliary clearance: FD70 was used as a nonabsorbable marker of the dosing solution to investigate MC. Under light ether anesthesia, 5 mL of 0.1z FD70 dissolved in Dex solution was instilled 1 cm from the nostril with a microsyringe. To collect FD in the nasal cavity, the esophagus and trachea were surgically operated according to the method of Hirai et al. 16) The trachea was cannulated with polyethylene tubing under intraperitoneal urethane (1500 mg W kg) anesthesia 5 min before the collection time (10, 20, 30 and 60 min). Another tube was inserted from the esophagus to the posterior part of the nasal cavity. The nasopalatine was closed with a surgical adhesive agent (Aron Alpha } , Sankyo Co., Japan). Samples were collected through the polyethylene tubing inserted from the esophagus. Collection procedures of FD were as follows: The nasal cavity was washed out with 4 mL of PBS, and thenˆlled with an appropriate volume of 50 mM DTT-PBS solution for 10 min. The nasal cavity was washed again with 4 mL of 50 mM DTT-PBS solution twice. DTT reduces disulˆde bridges of the mucosa 17) and removes the mucus layer of epithelial cells. The recovery of FD70 in the nasal cavity was conˆrmed as more than 98z by the procedure described above.
Nasal absorption of acyclovir: Under light ether anesthesia, the right femoral artery was cannulated with polyethylene tubing. Acyclovir dissolved in 5 mL of physiological saline was instilled 1 cm from the nostril with a microsyringe. The animal was kept in a cage (KN-326-III, Natsume, Tokyo, Japan) throughout the experiment. The animal usually became completely conscious 5-10 min after instillation. Blood samples were collected for 240 min after drug administration. During this period, the animal was allowed free access to water. Plasma was obtained by centrifugation. Culture of Caco-2 and preparation of Caco-2 monolayers Caco-2 cells were grown in Dulbecco's modiˆed Eagle's medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10z fetal bovine serum 1z L-glutamine, 1z non-essential amino acid and 5z antibioticantimycotic solution (all from Gibco Laboratories, Lenexa, KS, USA) in a culture ‰ask.
18)
Preparation of Caco-2 monolayer for normal transport study: Caco-2 monolayers were prepared according to the short-term culture method 19) using a culture kit, BIOCOAT } HTS Caco-2 Assay System (Beckton Dickinson Bioscience, Bedford, MA, USA). Brie‰y, the cells were harvested with trypsin-EDTA and seeded on â brillar collagen pre-coated cell culture insert (pore size: 1.0 mm, growth area: 0.9 cm 2 , 12 wells W plate) with seeding medium at a density of 4×10 5 cells W well. The seeding medium was changed with diŠerentiation medium 2 days' post-seeding. The diŠerentiation medium was changed everyday. The monolayer was used for the transport study 5-7 days after seeding.
Preparation of Caco-2 monolayer for modiˆed transport study: The cells were harvested with trypsin-EDTA and seeded on polycarbonateˆlters (pore size: 0.3 mm, growth area: 4.2 cm 2 , 6 wells W plate, Beckton Dickinson Bioscience, Bedford, MA, USA) with culture medium at a density of 2×10 5 cells W well. The culture medium was changed every 2 days. The monolayer was used for in vitro modiˆed transport study 16 days after seeding.
In vitro study on transepithelial transport
Hank's balanced salts solution (HBSS) supplemented with 15 mM glucose was used for transport studies after adjusting pH to 7.4 with HEPES. Dex (5z, 10z, 20z and 40z) and acyclovir (1 mM) were dissolved in transport medium and used in the study described below. Before the transport study, Caco-2 monolayers were preincubated with drug-free transport medium for 10 min at 379 C. All experiments were carried out at 379 C.
Normal transport study: Apical transport medium was replaced with transport medium (0.8 mL) containing acyclovir and Dex. Drug-free transport medium (2.0 mL) was added to the basal chamber; thereafter, an aliquot of the sample was taken from the basal chamber over 120 min. The same volume of fresh transport medium was added to maintain the basal volume constant. At the end of the experiments, apical solutions were taken to check the mass balance. Modiˆed transport study: After 10 min preincubation, the apical solution was completely removed. The volume of the basal solution was adjusted to 1.0 mL to avoid hydrostatic pressure on the monolayer. Each well of a 6-well plate was previouslyˆlled with 1.0 mL of normal transport medium. The transport study was started by applying 5 mL of the solution to the surface of the monolayer. The insert was transferred to the next well in the plate every 2 min for the initial 12 min, and 16 and 20 min thereafter. The transport medium in the well was taken for the analysis of acyclovir.
Calculation of the permeability of acyclovir: The permeability [apparent permeability coe‹cient, PCaco-2 (cm W sec)] of acyclovir was calculated according to the following equation:
where d Q W dt is the appearance rate of drugs in the basal chamber ( mmol W sec), C0 is the initial drug concentration in the apical chamber (mM), and A is the surface area of the monolayer (0.9 cm 2 ). Drug Assay FITC-dextran: The volume of the nasal washing was precisely adjusted to 5 mL. Afterˆltrating the samples through a membraneˆlter (pore size; 0.45 mm, Millex } , Millipore Co., MA), the ‰uorescent intensity of FD70 was determined (excitation; 495 nm and emission; 520 nm) using a ‰uorescence spectrometer (F-2500, Hitachi Co., Tokyo, Japan).
Acyclovir: Methanol (1200 mL) was added to the plasma (100 mL) for deprotenization and the mixture was centrifuged. The supernatant (1000 mL) was taken for analysis with an LC W MS system (API1100, Agilent Technologies, Boeblingen, Germany) equipped with a reversed phase column (Inertsil } ODS-3, 2.1×150 mm, GL Sciences Inc., Tokyo, Japan). The mobile phase consisted of 10 mM ammonium acetate-methanol (95:5) at a ‰ow rate of 0.25 mL W min. The injection volume was 20 mL. The detection limit of acyclovir was 5 ngW mL under this analytical condition. With regard to samples from in vitro transport study, 20 mL was directly injected to LC W MS without any treatment.
Results and Discussion
Viscosity of Dex solutions
The Table lists the viscosity of Dex solutions. The viscosity of the dosing solution used in this study ranged between 0.1 and 147 mPa･sec and increased exponentially with the increase in Dex concentration. 40z Dex solution showed the highest viscosity (147 mPa･sec) and was one order of magnitude larger than that of 20z Dex solution (15.9 mPa･sec). The viscosity of 0.1z FD70 solution (data not shown) was the same as PBS (control in Table, 1.02 mPa･sec), indicating that the addition of 0.1z FD70 does not aŠect the viscosity of the solution. In addition to viscosity, the osmolarity of the solution changed by the addition of Dex. The direct measurement and calculation based on van't HoŠ equation clariˆed the small diŠerence in osmolarity between Dex solutions. The eŠect of the osmolarity of the solution on in vivo absorption and in vitro permeation is assumed to be negligible in this study. EŠect of viscosity of the application solution on mucociliary clearance of FD70 Figure 1 indicates the disappearance proˆles of FD70 from the rat nasal cavity after nasal administration. The proˆles of the control showed mono-exponential elimination. On the other hand, the elimination of FD applied with 5z Dex, 10z Dex, 20z Dex and 40z Dex solutions showed biexponential elimination. The initial decline was similar to the control. Mean resistance times (MRT) of FD70 in the nasal cavity are shown in the Table. MRT of FD70 in the nasal cavity was approximately 20 min in the control. With the increase in Dex concentration, MRT of FD70 was increased. The slow elimination in the second phase largely contributed to the increase in MRT.
The disappearance of FD70 is based on the movement of the mucus to the nasopharynx. Mucus is driven by the ciliary beat. Due to the characteristics of the ciliary beat, the movement velocity of the mucus is dependent on the depth from the surface. 20) The shallower the depth, the faster the mucus moves. FD70 diŠused into the mucus after application onto the mucosal surface; therefore, the disappearance of FD70 is dependent on how fast the solution spreads over the surface, diŠusion into the mucus and mucus clearance to the nasopharynx. The mechanism is very complex. The reason for the qualitative diŠerence in disappearance proˆles of FD70 by Dex addition is not clear at present. To clarify the details of the biexponential elimination of FD70, an in vitro system to investigate MC should be developed. EŠect of viscosity of application solution on nasal absorption of acyclovir Figure 2 shows the proˆles of the plasma concentration of acyclovir as a function of time following nasal application. In previous research, 15) 5 model drugs were used to develop a kinetic theory to evaluate nasal and intestinal absorption. In this research, acyclovir was selected as the model drug, since it has a moderate PCaco-2 among the 5 drugs. When acyclovir was nasally applied with 5z and 10z Dex solutions (abbreviated as ACV-5z and ACV-10z, respectively), the proˆles were similar to the control. Theseˆndings were due to the small increase in the viscosity of 5z and 10z Dex solutions; however, when acyclovir was applied nasally with 20z or 40z Dex solution (abbreviated as ACV-20z and ACV-40z, respectively), the proˆles showed a diŠerence from the control. Absorption is enhanced at ACV-20z and inhibited at ACV-40z. The Table lists AUC as an index of nasal drug absorption. According to AUC, absorption was similar at ACV-5z, slightly increased at ACV-10z, further increased at ACV-20z and markedly decreased at ACV-40z in comparison with the control. The increase in absorption of ACV-20z was likely due to the longer residence of acyclovir in the nasal cavity. Since MRT of 40z Dex solution is larger than 20z Dex solution, the decrease in the absorption of ACV-40z is due to the predominance of some adverse factors over longer MRT of 40z Dex solution.
The surface of nasal epithelial cells is covered with mucus. The penetration rate of Dex solution into mucus following nasal instillation relates to how close the drug can approach the cell surface. One of the factors determining the penetration rate into mucus is the viscosity of the solution. With the increase in the viscosity of applied Dex solution, the penetration rate of the solution into mucus is considered to be decreased, resulting in a delay of the drug's approach to the cell surface. The degree of the increase in the viscosity of the 40z Dex solution is remarkable in comparison with other Dex solutions. This may be one reason why the in vivo absorption of ACV from 40z Dex solution is decreased.
According to Zaki et al., the increased viscosity of the dosing solution by hydroxylpropyl methylcellulose adversely aŠects the nasal absorption of metoclopramide, 21) which originally showed good absorption from the nasal cavity (more than 90z by 60 min). Although the diŠerence in the experimental design of the animal study such as dosing volume and anesthesia of the rat must be considered carefully, theirˆndings on metoclopramide are in agreement with acyclovir. The eŠect of viscosity on the nasal absorption of the highly permeable drug is likely negative. EŠect of viscosity of application solution on transepithelial transport of acyclovir Figure 3 shows the permeation proˆles of acyclovir derived from normal and modiˆed Caco-2 systems. In the normal system (left panel in Fig. 3 ), the permeation of acyclovir was markedly decreased by Dex. The diŠerence in permeation is very small in Dex solution with a concentration of more than 10z. PCaco-2 of 10z, 20z and 40z Dex solutions was markedly small compared with the control and 5z Dex solution, as shown in the Table. Theseˆndings suggest that a factor other than diŠusion in the solution and permeation across Caco-2 is a determinant of in vivo nasal absorption. One of the factors governing drug transepithelial transport is the area through which the drug can permeate. In the normal system, the diŠusion area of the drug on Caco-2 is constant (0.9 cm 2 ). The viscosity of the solution can in‰uence the surface area where the drug solution can spread in the rat nasal cavity in vivo. Based on these considerations, the Caco-2 system was modiˆed. The apical solution of the transwell insert was completely removed. Five microliters of solution, the same volume as the in vivo animal study, was applied directly to the surface of the Caco-2 monolayer. Permeation proˆles up to 20 min derived from the modiˆed Caco-2 system are also indicated in Fig. 3 . DiŠerences in the permeations of acyclovir from control, 5z, 10z and 20z Dex solutions were very small. In contrast, the permeation of acyclovir from 40z Dex solution was signiˆcantly decreased and a lag time, which was approximately 2 min, was observed in the permeation proˆle. Thisˆnding is consistent with the decrease in the nasal absorption of ACV-40z. Consequently, the adverse eŠect of 40z Dex solution on the in vivo nasal absorption of acyclovir is partly due to the decrease in the area where the dosing solution can spread and its rate.
In conclusion, the residence of the applied solution in the rat nasal cavity was enhanced by the addition of Dex. The increase in the residence time is dependent on the viscosity of the solution. It was also clariˆed that moderate viscosity of the dosing solution improved in vivo nasal absorption of acyclovir, while higher viscosity of the application solution decreased it. The results from the modiˆed Caco-2 transport study suggest that this may be due to diŠerences in the absorption surface area.
